We recently identified a novel link between hypoxia, which is a hallmark of human malignancies, and cancer cell metabolism. We showed that hypoxia dramatically induces a previously under-appreciated metabolic pathway in cancer cells, namely the generation of cytosolic Acetyl-Coa (AcCoA) by reductive carboxylation of cytosolic ?-ketoglutarate (?KG) to isocitrate. Our preliminary data indicate that Isocitrate Dehydrogenase 1, an enzyme mutated in gliomas and acute leukemias, is necessary for this phenomenon and that the transcription factors Hypoxia Inducible Factors (HIFs) and the hypoxia-regulated cytosolic enzyme Aco1 are likely implicated in mediating this hypoxia effect. Our work highlights that hypoxia-induced metabolic changes of cancer cells present an opportunity for development of therapies targeting a broad range of human malignancies. In this application we propose to dissect the molecular mechanism(s) mediating the hypoxia-induced reductive carboxylation by and to validate critical enzymes of reductive carboxylation as therapeutic targets for tumor suppression in vivo.

Public Health Relevance

Cancer cells have a metabolism which differs from the metabolism of normal cells. In addition, almost all cancers learn how to grow in hypoxic environments. We discovered a new mechanism that links hypoxia and cancer cell metabolism and we propose experiments that will highlight the molecular mechanisms of this link and will identify critical proteins that can target this mechanism for anti-cancer therapy. This is an underappreciated area of work that opens new opportunities for cancer therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA160458-03
Application #
8657912
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Salnikow, Konstantin
Project Start
2012-07-20
Project End
2017-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
3
Fiscal Year
2014
Total Cost
$309,781
Indirect Cost
$68,251
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Okazaki, Arimichi; Gameiro, Paulo A; Christodoulou, Danos et al. (2017) Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers. J Clin Invest 127:1631-1645
Davidson, Shawn M; Jonas, Oliver; Keibler, Mark A et al. (2017) Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nat Med 23:235-241
Dong, Wentao; Keibler, Mark A; Stephanopoulos, Gregory (2017) Review of metabolic pathways activated in cancer cells as determined through isotopic labeling and network analysis. Metab Eng 43:113-124
Berrios, Christian; Padi, Megha; Keibler, Mark A et al. (2016) Merkel Cell Polyomavirus Small T Antigen Promotes Pro-Glycolytic Metabolic Perturbations Required for Transformation. PLoS Pathog 12:e1006020
Noonan, Haley R; Metelo, Ana M; Kamei, Caramai N et al. (2016) Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma. Dis Model Mech 9:873-84
Keibler, Mark A; Wasylenko, Thomas M; Kelleher, Joanne K et al. (2016) Metabolic requirements for cancer cell proliferation. Cancer Metab 4:16
Vasdekis, Andreas E; Stephanopoulos, Gregory (2015) Review of methods to probe single cell metabolism and bioenergetics. Metab Eng 27:115-35
Vasdekis, A E; Silverman, A M; Stephanopoulos, G (2015) Origins of Cell-to-Cell Bioprocessing Diversity and Implications of the Extracellular Environment Revealed at the Single-Cell Level. Sci Rep 5:17689
Buescher, Joerg M; Antoniewicz, Maciek R; Boros, Laszlo G et al. (2015) A roadmap for interpreting (13)C metabolite labeling patterns from cells. Curr Opin Biotechnol 34:189-201
Metelo, Ana Martins; Noonan, Haley; Iliopoulos, Othon (2015) HIF2a inhibitors for the treatment of VHL disease. Oncotarget 6:23036-7

Showing the most recent 10 out of 40 publications